Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sana Biotechnology Inc SANA

Healthcare Biotechnology
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product... see more

Recent & Breaking News (NDAQ:SANA)

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

GlobeNewswire June 17, 2022

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

GlobeNewswire June 13, 2022

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

GlobeNewswire June 7, 2022

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory

GlobeNewswire June 1, 2022

Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado's Gates Institute

GlobeNewswire May 12, 2022

Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

GlobeNewswire May 10, 2022

Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference

GlobeNewswire May 4, 2022

Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

GlobeNewswire May 2, 2022

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

GlobeNewswire March 16, 2022

Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire March 9, 2022

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting

GlobeNewswire March 8, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

PR Newswire February 15, 2022

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

GlobeNewswire January 11, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

GlobeNewswire January 10, 2022

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies

PR Newswire December 17, 2021

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

GlobeNewswire December 12, 2021

Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates

GlobeNewswire November 8, 2021

Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

GlobeNewswire November 4, 2021

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs

GlobeNewswire October 19, 2021